Wickline Mihkai, McErlean Gemma, Carpenter Paul A, Iribarren Sarah, Reding Kerryn, Berry Donna L
University of Washington School of Nursing/Fred Hutchinson Cancer Center, Seattle, Washington.
St George Hospital and School of Nursing, University of Wollongong, Loftus, New South Wales, Australia.
Transplant Cell Ther. 2024 Mar;30(3):268-280. doi: 10.1016/j.jtct.2023.11.009. Epub 2023 Nov 11.
Post-transplantation revaccination uptake of childhood vaccines in adult hematopoietic stem cell transplantation (HSCT) survivors is suboptimal, increasing the risk of infectious morbidity and mortality within this population. We systematically reviewed the literature for factors related to revaccination uptake, as well as the barriers and facilitators that affect successful revaccination. We conducted a scoping review searching PubMed, CINAHL, Embase, and Web of Science in March 2023. Two independent reviewers performed study selection using the complete dual review process. Data were extracted using a standard form. Factors were characterized as demographic, clinical, or social determinants of health that affected revaccination uptake. Barriers and facilitators were categorized using the constructs from the World Health Organization Behavioural and Social Drivers Framework. Our searches yielded 914 sources, from which 15 publications were selected (5 original research and 10 quality improvement initiatives). More than one-half of the reports listed factors associated with poorer uptake, predominately clinical factors, followed by social determinants of health, then demographic factors. Nearly all the reports described barriers to successful revaccination uptake, with most of these falling into the "practical issues" construct. Most of the reports described facilitators, nearly all related to health care system improvements associated with improved revaccination uptake. Although this review provides a good starting point for understanding impediments to successful revaccination after HSCT, this review reveals that we lack sufficient evidence to drive targeted interventions to improve uptake. More research is needed, focusing on survivors' voices to inform our knowledge of barriers and facilitators to complete revaccination after HSCT, exploring behavioral and social drivers within this population, and examining the care delivery models that may complicate vaccine delivery in this population.
成年造血干细胞移植(HSCT)幸存者中儿童疫苗移植后重新接种的接受率不理想,增加了该人群感染性发病和死亡的风险。我们系统地回顾了与重新接种接受率相关的因素,以及影响成功重新接种的障碍和促进因素。我们于2023年3月在PubMed、CINAHL、Embase和科学网进行了范围界定审查。两名独立评审员采用完全双重评审流程进行研究筛选。数据采用标准表格提取。因素被表征为影响重新接种接受率的人口统计学、临床或健康社会决定因素。障碍和促进因素使用世界卫生组织行为和社会驱动因素框架中的结构进行分类。我们的检索产生了914个来源,从中选择了15篇出版物(5篇原创研究和10项质量改进倡议)。超过一半的报告列出了与接受率较低相关的因素,主要是临床因素,其次是健康社会决定因素,然后是人口统计学因素。几乎所有报告都描述了成功重新接种接受的障碍,其中大多数属于“实际问题”结构。大多数报告描述了促进因素,几乎所有促进因素都与与提高重新接种接受率相关的医疗保健系统改善有关。尽管本综述为理解HSCT后成功重新接种的障碍提供了一个良好的起点,但本综述表明,我们缺乏足够的证据来推动有针对性的干预措施以提高接受率。需要更多的研究,重点关注幸存者的声音,以了解HSCT后完成重新接种的障碍和促进因素,探索该人群中的行为和社会驱动因素,并研究可能使该人群疫苗接种复杂化的护理提供模式。